Shares of the Marlborough-based medical device giant (NYSE: BSX) were up 8 percent in after hour trading on the news, which brings closure to litigation which has been hanging over its head since its 2006 acquisition of Guidant.
J&J (NYSE: JNJ) claimed in the lawsuit that Guidant, for which Boston Scientific paid $27 billion, broke the terms of an earlier contract to be acquired by J&J by providing information to BSX. The New Jersey company claimed its damages from the failed merger were $4.35 billion plus interest, for a t...
07:15 Telefonica to sell up to 40 percent of Telxius to KKR for 1.3 billion euros19
09:14 Airbus seeks new talks with European nations over A400M costs15
14:29 Unilever rejects $143 billion Kraft Heinz bid as without merit20
12:33 Kraft Heinz to pursue merger despite Unilever rejection19